Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

13.04
-0.4100-3.05%
Volume:683.06K
Turnover:9.02M
Market Cap:1.23B
PE:-4.13
High:13.83
Open:13.69
Low:12.80
Close:13.45
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.33
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.63
PE(LYR):-3.85

Loading ...

Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss

MT Newswires Live
·
Aug 14

Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate

Benzinga Earnings
·
Aug 14

Replimune FY27 Q1 Net Loss Narrows to $69.8 Million; R&D Expenses Fall to $49.3 Million

Reuters
·
Aug 14

Replimune Group Q1 EPS USD -0.72

THOMSON REUTERS
·
Aug 14

Baker Bros. Advisors Membeli Saham Replimune Senilai USD 33,01 Juta

Reuters
·
Aug 12

Replimune Amends Filing to Correct Pre-Funded Warrant Beneficial Ownership Limits

Reuters
·
Aug 11

Replimune Shares Rise After Pricing of Offering

Dow Jones
·
Aug 11

Replimune Jumps After $150 Mln Equity Offering for Skin Cancer Drug

Reuters
·
Aug 11

Replimune Group, - Prices Offering of 9.7 Mln Shares at $12.06 Per Share

THOMSON REUTERS
·
Aug 10

Replimune Group, - Offers 2.7 Mln Pre-Funded Warrants at $12.06 Per Warrant

THOMSON REUTERS
·
Aug 10

Replimune Prices USD 150 Million Follow-on Stock Offering at USD 12.06 Per Share

Reuters
·
Aug 10

Replimune Group Price Target Raised to $20.00/Share from $17.00 by JP Morgan

Dow Jones
·
Aug 08

U.S. Stocks on the MOVE-Atlassian, Macerich, DoubleVerify

Reuters
·
Aug 08

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.

Dow Jones
·
Aug 08

Replimune Slides as FDA Approval Label Tempers Enthusiasm

Reuters
·
Aug 07

Replimune Group, Inc. : Wedbush Raises to Outperform from Neutral; Raises Target Price to $19 from $12

THOMSON REUTERS
·
Aug 07

Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts PT to $19 From $12

MT Newswires Live
·
Aug 07

Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma

TIPRANKS
·
Aug 07

Zentalis Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Replimune Group Melanoma Therapy Tudriqev Priced at $450,000 Per Typical Real-World Patient

THOMSON REUTERS
·
Aug 07